Back to Top
ADVANCING THE FUTURE OF CANCER TREATMENT
At ichorbio, we understand that developing the next breakthrough therapy requires reliable tools and scalable solutions. Our comprehensive range of research biosimilars and in vivo antibodies supports your journey from initial screening through preclinical development, helping you validate targets and accelerate your pipeline with confidence.
FEATURED PRODUCT CATEGORIES
CITED BY TEAMS AT
Loading...
RESEARCH BIOSIMILARS
Comprehensive Research Biosimilars
Transform your therapeutic development process with our extensive portfolio of research-grade biosimilars. Whether you're developing new checkpoint inhibitors or exploring novel combination therapies, our validated antibodies provide the reliable benchmarking tools you need. Every product is backed by detailed analytical data, supporting your regulatory documentation requirements and accelerating your path to clinical trials.
ANTI-HUMAN ANTIBODIES
Validated In Vivo Solutions
Move your research forward with our selection of in vivo antibodies, specifically developed for preclinical research. Each batch undergoes rigorous testing and is provided with comprehensive documentation, enabling seamless integration into your development pipeline. Our bulk supply capabilities ensure consistent availability throughout your development journey.
Making cancer research faster and more cost effective.
Delivering research biosimilars at a faster rate to allow you to iterate your experiments quicker.
Ready to accelerate your development pipeline?
ISOTYPE CONTROLS
Essential Controls for Validated Research
Success in therapeutic development demands reproducible results. Our isotype controls are manufactured to the same exacting standards as our research antibodies, with low endotoxin levels suitable for in vivo applications. Available in bulk quantities, they provide the experimental validation needed for confidence in your research outcomes.
NEW PRODUCTS
View More
At the coalface of I-O research - biosimilars, bispecifics, ADCs, in vivo antibodies and isotype controls.
ANTI-HUMAN ANTIBODIES
Scaling Your Bioprocess Development
For biotechnology companies and contract research organizations, our bulk anti-human antibodies deliver the consistent quality and scale needed for process development. With low endotoxin levels and gram-scale availability, these tools support your manufacturing development while maintaining cost-effectiveness. Our technical team provides expertise for seamless integration into your workflows.
CITATIONS
Latest Publications Featuring ichorbio Products
Loading...
Your Partner in Development
From early-stage research through preclinical development, ichorbio provides the tools and support you need to advance your pipeline. Our commitment to quality, comprehensive documentation, and reliable bulk supply helps accelerate your journey from innovative concept to breakthrough therapy.
OUR BLOG
-
Posted: December 17, 2024Categories: ichorbio Citations (Resources)
Read more »eNAMPT Drives Abnormal Blood Vessel Formation in Triple-Negative Breast Cancer Through Direct Effects on Pericytes
A groundbreaking study published in Angiogenesis reveals a previously unknown mechanism by which extracellular nicotinamide phosphoribosyltransferase (eNAMPT) promotes tumor progression through direct effects on blood vessel formation. The research team...
-
Posted: December 17, 2024Categories: ichorbio Citations (Resources)
Read more »Breakthrough in De Novo Antibody Design Achieves Therapeutic-Grade Properties
A transformative paper from Nabla Bio demonstrates a significant leap forward in computational antibody design, showing that de novo methods can now achieve therapeutic-grade properties without experimental optimization. Their system, called JAM (Joint Atomic Modeling), represents a major...
-
Posted: November 25, 2024Categories: in vivo research
Read more »Therapeutic Applications of Immunoglobulin Isotypes: Current Understanding and Future Directions
Introduction
The therapeutic monoclonal antibody landscape has expanded dramatically over the past decades, driven by our deepening understanding of immunoglobulin biology and advances in protein...
